Di-n-propyl phthalate (DnPP) is a synthetic organic compound, a diester of phthalic acid with propanol. It is a colorless, odorless, and viscous liquid at room temperature. DnPP is primarily used as a plasticizer, adding flexibility and durability to plastics. It is also used as a solvent, and in some instances, as a pesticide. DnPP is not naturally occurring and is therefore introduced into the environment through human activities, primarily from the production and disposal of plastics. DnPP can be found in the environment in various media including water, soil, and air. DnPP is a persistent organic pollutant (POP), meaning it does not readily break down in the environment. DnPP is associated with health risks such as reproductive toxicity, endocrine disruption, and potential carcinogenicity. It is studied extensively to understand its environmental fate, toxicity, and potential impacts on human and ecosystem health. Research on DnPP focuses on its synthesis, environmental distribution, bioaccumulation, biodegradation, and toxicological effects.'
di-n-propylphthalate: RN & Structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
dipropyl phthalate : A phthalate ester that is the dipropyl ester of benzene-1,2-dicarboxylic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 8559 |
| CHEMBL ID | 1483029 |
| CHEBI ID | 60069 |
| SCHEMBL ID | 112063 |
| MeSH ID | M0277421 |
| Synonym |
|---|
| BIDD:ER0350 |
| AKOS015838979 |
| nsc-15314 |
| phthalic acid, dipropyl ester |
| di-n-propyl phthalate |
| 1, dipropyl ester |
| dipropyl phthalate |
| 131-16-8 |
| nsc15314 |
| 1,2-benzenedicarboxylic acid, dipropyl ester |
| di-n-propylphthalate |
| NCGC00090783-01 |
| ai3-01767 |
| nsc 15314 |
| einecs 205-015-8 |
| n-dipropyl phthalate |
| brn 2332522 |
| MLS002222366 |
| smr001307293 |
| dipropyl phthalate, 98% |
| NCGC00090783-02 |
| 1,2-benzenedicarboxylic acid dipropyl ester |
| CHEBI:60069 , |
| phthalic acid di-n-propyl ester |
| dipropyl benzene-1,2-dicarboxylate |
| phthalic acid dipropyl ester |
| P0306 |
| NCGC00090783-03 |
| 1,2-benzenedicarboxylic acid, 1,2-dipropyl ester |
| unii-8usp5y77ss |
| 4-09-00-03174 (beilstein handbook reference) |
| 8usp5y77ss , |
| HMS3039L17 |
| cas-131-16-8 |
| dtxcid3011133 |
| tox21_303379 |
| NCGC00257273-01 |
| dtxsid5031133 , |
| NCGC00259211-01 |
| tox21_201662 |
| FT-0625198 |
| EPITOPE ID:138713 |
| CHEMBL1483029 |
| SCHEMBL112063 |
| dipropyl ester1,2-benzenedicarboxylic acid |
| MQHNKCZKNAJROC-UHFFFAOYSA-N |
| phthalic acid, di-n-propyl ester |
| mfcd00009371 |
| dipropylphthalate |
| dipropyl phthalate, pestanal(r), analytical standard |
| phthalic acid, bis-propyl ester |
| J-005947 |
| dipropyl phtalate |
| BS-15188 |
| Q27127053 |
| nsc 15314;di-n-propyl phthalate |
| D94471 |
| CS-0014049 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " In particular, the diethyl (DEP), di-n-propyl (DnPP), and di-n-butyl (DBP) phthalates were found to exert detrimental effects in both mammalian and non-mammalian studies, with toxic effects varying according to alkyl chain length." | ( Assessing differences in toxicity and teratogenicity of three phthalates, Diethyl phthalate, Di-n-propyl phthalate, and Di-n-butyl phthalate, using Xenopus laevis embryos. Burnham, N; Gardner, ST; Lester, R; Onkst, PE; Perygin, DH; Rayburn, J; Wood, AT, 2016) | 0.43 |
| Class | Description |
|---|---|
| phthalate ester | |
| diester | A diester is a compound containing two ester groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 0.3857 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 35.4813 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 31.6228 | 0.0002 | 14.3764 | 60.0339 | AID588533 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 14.7315 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 55.8160 | 0.0002 | 29.3054 | 16,493.5996 | AID743075 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 34.9013 | 0.0016 | 28.0151 | 77.1139 | AID1224843 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 22.3872 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| geminin | Homo sapiens (human) | Potency | 25.9290 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 15.3553 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 35.4813 | 3.9811 | 46.7448 | 112.2020 | AID720708 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.14) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||